Skip to main content

Advertisement

SpringerLink
Log in

Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Tumor necrosis factor alpha (TNFα) has broad effects on the immune system including lymphoid organ development as well as growth, survival und function of immune cells. TNFα has two main functions: regulatory effects and proinflammatory activities. In several diseases such as juvenile and adult “rheumatoid” arthritis, psoriasis and chronic inflammatory bowel disease, the application of TNFα-blocking medications has been beneficial. However, induction of inflammation in several organs including the eye, CNS, skin and gastrointestinal tract has been reported. We report on an 11-year-old girl with juvenile idiopathic arthritis, who developed Crohn’s disease (CD) while taking etanercept for her arthritis. Etanercept was discontinued and an antibody-based anti-TNF treatment using adalimumab was started, which induced remission of the gastrointestinal symptoms promptly. This case indicates that immunodysregulatory and even proinflammatory effects of etanercept are of relevance in the clinical practice. Furthermore, TNFα as a part of its function seems to downregulate mucosal inflammation in CD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Beutler BA (1999) The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 57:16–21

    CAS  PubMed  Google Scholar 

  2. Oh J, Arkfeld DG, Horwitz DA (2005) Development of Crohn’s disease in a patient taking etanercept. J Rheumatol 32:752–753

    PubMed  Google Scholar 

  3. Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA registry. Ann Rheum Dis 68:519–525

    Article  CAS  PubMed  Google Scholar 

  4. Prince FH, Twilt M, Ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 68:635–641

    Article  CAS  PubMed  Google Scholar 

  5. Song IH, Appel H, Haibel H et al (2008) New onset of Crohn’s disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35:532–536

    CAS  PubMed  Google Scholar 

  6. Zou J, Rudwaleit M, Brandt J et al (2003) Up regulation of the production of tumour necrosis factor alpha and interferon gamma by t cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 62:561–564. doi:10.1136/ard.62.6.561

    Article  CAS  PubMed  Google Scholar 

  7. Gerloni V, Pontikaki I, Gattinara M et al (2008) Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 67:1145–1152. doi:10.1136/ard.2007.069484

    Article  CAS  PubMed  Google Scholar 

  8. Ruemmele FM, Prieur AM, Talbotec C et al (2004) Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 39:203–206. doi:10.1097/00005176-200408000-00016

    Article  CAS  PubMed  Google Scholar 

  9. Sandborn WJ, Rutgeerts P, Enns R et al (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838

    PubMed  Google Scholar 

  10. Lugering A, Schmidt M, Lugering N et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121:1145–1157. doi:10.1053/gast.2001.28702

    Article  CAS  PubMed  Google Scholar 

  11. Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab, but not etanercept, induces apoptosis in lamina propria T lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785. doi:10.1016/S0016-5085(03)00382-2

    Article  PubMed  Google Scholar 

  12. Sfikakis PP, Iliopoulos A, Elezoglou A et al (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513–2518. doi:10.1002/art.21233

    Article  CAS  PubMed  Google Scholar 

  13. Kunzmann S, Warmuth-Metz M, Girschick HJ (2005) Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still’s disease. Scand J Rheumatol 34:76–78. doi:10.1080/03009740510017887

    Article  CAS  PubMed  Google Scholar 

  14. Mohan N, Edwards ET, Cupps TR et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862–2869. doi:10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W

    Article  CAS  PubMed  Google Scholar 

  15. Charles PJ, Smeenk RJ, De Jong J et al (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390. doi:10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D

    Article  CAS  PubMed  Google Scholar 

  16. Sfikakis PP, Kollias G (2003) Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 15:380–386. doi:10.1097/00002281-200307000-00003

    Article  CAS  PubMed  Google Scholar 

  17. Russell RK, Wilson DC, Satsangi J (2004) Unravelling the complex genetics of inflammatory bowel disease. Arch Dis Child 89:598–603. doi:10.1136/adc.2003.041046

    Article  CAS  PubMed  Google Scholar 

  18. Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346–357. doi:10.1016/S1568-9972(03)00048-X

    Article  CAS  PubMed  Google Scholar 

  19. Cavanaugh J (2006) Nod2: ethnic and geographic differences. World J Gastroenterol 12:3673–3677

    PubMed  Google Scholar 

  20. Neurath MF, Fuss I, Pasparakis M et al (1997) Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27:1743–1750. doi:10.1002/eji.1830270722

    Article  CAS  PubMed  Google Scholar 

  21. de Ridder L, Benninga MA, Taminiau JA et al (2006) Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 43:388–390. doi:10.1097/01.mpg.0000226369.31956.bf

    Article  PubMed  Google Scholar 

  22. Hyrich KL, Symmons DP, Watson KD et al (2006) Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics register. Arthritis Rheum 54:1786–1794. doi:10.1002/art.21830

    Article  CAS  PubMed  Google Scholar 

  23. Wyneski MJ, Green A, Kay M et al (2008) Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 47:19–25

    Article  CAS  PubMed  Google Scholar 

  24. Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810–820. doi:10.1056/NEJMoa0706290

    Article  CAS  PubMed  Google Scholar 

  25. Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285. doi:10.1001/jama.295.19.2275

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Rheumatology, Immunology, Gastroenterology and Infectious Diseases, Children’s Hospital, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    V. Wiegering, H. Morbach, A. Dick & H. J. Girschick

Authors
  1. V. Wiegering
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Morbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Dick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. J. Girschick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. J. Girschick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiegering, V., Morbach, H., Dick, A. et al. Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 30, 801–804 (2010). https://doi.org/10.1007/s00296-009-0991-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-0991-7

Keywords

Search

Navigation